VRTX Stock — Vertex Pharmaceuticals Inc.

Vertex Pharmaceuticals Inc. (VRTX)

Updated October 16, 2026.

VRTX is a Stock. Total return is 11005.3% over the past 35.2 years.

Vertex Pharmaceuticals is a biotechnology company that discovers, develops, and commercializes medicines for serious diseases including cystic fibrosis, sickle cell disease, beta thalassemia, and acute pain, with marketed products such as TRIKAFTA and CASGEVY alongside a pipeline of clinical-stage candidates in areas like kidney disease and diabetes. The company does not currently have an established dividend distribution program. Vertex appeals primarily to growth-oriented investors seeking exposure to specialty pharmaceuticals and rare disease treatments rather than income-focused investors.

VRTX performance

Price and return data through 2026-10-16.

Total return is 11005.3% over the past 35.2 years. Over the past year its total return — price change plus distributions reinvested — is 22.3%. Its deepest 1-year drawdown was 15.2%.

VRTX key facts

Asset type

Stock

Asset class

Equity

Inception date

07/24/1991

Distribution frequency

None

Last close

$499.74 (as of 2026-10-16)

Market cap

$126,664,562,160

Average volume

1408420.0

Beta

0.281

Payout ratio

0.0%

P/E ratio

28.94

Forward P/E

24.0964

EPS

$17.27

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

VRTX risks and drawbacks

The deepest 1-year drawdown on record here is 15.2%.

Who may consider VRTX — and who may not

It is a weaker fit for investors who need monthly cash flow (VRTX does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on VRTX

• ETFs holding VRTX
• All tickers starting with V

Tagged: Pharmaceutical.

Frequently asked questions